New 25-Valent pneumonia vaccine shows promise in phase 2 trial
⭐️ VACCINE ⭐️
Completed
This study tested a new vaccine designed to protect against 25 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 220 healthy adults aged 18 to 49 received either the new vaccine or an existing one to compare safety and immune response. …
Phase: PHASE2 • Sponsor: Inventprise Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:02 UTC